Literature DB >> 30263856

Building on the Shoulders of Giants: Is the use of Early Spontaneous Ventilation in the Setting of Severe Diffuse Acute Respiratory Distress Syndrome Actually Heretical?

Fabrice Petitjeans1, Cyrille Pichot2, Marco Ghignone3, Luc Quintin2.   

Abstract

Acute respiratory distress syndrome (ARDS) is not a failure of the neurological command of the ventilatory muscles or of the ventilatory muscles; it is an oxygenation defect. As positive pressure ventilation impedes the cardiac function, paralysis under general anaesthesia and controlled mandatory ventilation should be restricted to the interval needed to control the acute cardio-ventilatory distress observed upon admission into the critical care unit (CCU; "salvage therapy" during "shock state"). Current management of early severe diffuse ARDS rests on a prolonged interval of controlled mechanical ventilation with low driving pressure, paralysis (48 h, too often overextended), early proning and positive end-expiratory pressure (PEEP). Therefore, the time interval between arrival to the CCU and switching to spontaneous ventilation (SV) is not focused on normalizing the different factors involved in the pathophysiology of ARDS: fever, low cardiac output, systemic acidosis, peripheral shutdown (local acidosis), supine position, hypocapnia (generated by hyperpnea and tachypnea), sympathetic activation, inflammation and agitation. Then, the extended period of controlled mechanical ventilation with paralysis under general anaesthesia leads to CCU-acquired pathology, including low cardiac output, myoneuropathy, emergence delirium and nosocomial infection. The stabilization of the acute cardio-ventilatory distress should primarily itemize the pathophysiological conditions: fever control, improved micro-circulation and normalized local acidosis, 'upright' position, minimized hypercapnia, sympathetic de-activation (normalized sympathetic activity toward baseline levels resulting in improved micro-circulation with alpha-2 agonists administered immediately following optimized circulation and endotracheal intubation), lowered inflammation and 'cooperative' sedation without respiratory depression evoked by alpha-2 agonists. Normalised metabolic, circulatory and ventilatory demands will allow one to single out the oxygenation defect managed with high PEEP (diffuse recruitable ARDS) under early spontaneous ventilation (airway pressure release ventilation+SV or low-pressure support). Assuming an improved overall status, PaO2/FiO2≥150-200 allows for extubation and continuous non-invasive ventilation. Such fast-tracking may avoid most of the CCU-acquired pathologies. Evidence-based demonstration is required.

Entities:  

Keywords:  APRV; ARDS; alpha-2 agonist; clonidine; controlled mechanical ventilation; cooperative sedation; dexmedetomidine; high PEEP; low tidal volume; pressure support; spontaneous breathing; sympathetic de-activation; transpulmonary pressure

Year:  2018        PMID: 30263856      PMCID: PMC6157981          DOI: 10.5152/TJAR.2018.01947

Source DB:  PubMed          Journal:  Turk J Anaesthesiol Reanim        ISSN: 2149-276X


  100 in total

Review 1.  Respiratory sinus arrhythmia: why does the heartbeat synchronize with respiratory rhythm?

Authors:  Fumihiko Yasuma; Jun-Ichiro Hayano
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

Review 2.  Effects of mechanical ventilation on the extracellular matrix.

Authors:  Paolo Pelosi; Patricia R Rocco
Journal:  Intensive Care Med       Date:  2008-02-09       Impact factor: 17.440

3.  Noninvasive Failure in De Novo Acute Hypoxemic Respiratory Failure: High Positive End-Expiratory Pressure-Low Pressure Support, i.e., "Inverted Settings"?

Authors:  Fabrice Petitjeans; Luc Quintin
Journal:  Crit Care Med       Date:  2016-11       Impact factor: 7.598

Review 4.  Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management.

Authors:  Takeshi Yoshida; Yuji Fujino; Marcelo B P Amato; Brian P Kavanagh
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

5.  When to promote spontaneous respiratory activity in acute respiratory distress patients?

Authors:  Takeshi Yoshida; Laurent Papazian
Journal:  Anesthesiology       Date:  2014-06       Impact factor: 7.892

Review 6.  Sedation in intensive care: should we reach for dexmedetomidine sooner?

Authors:  Christopher Cann; David Melia
Journal:  Br J Hosp Med (Lond)       Date:  2017-10-02       Impact factor: 0.825

7.  Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis.

Authors:  A Vieillard-Baron; J M Schmitt; R Augarde; J L Fellahi; S Prin; B Page; A Beauchet; F Jardin
Journal:  Crit Care Med       Date:  2001-08       Impact factor: 7.598

8.  Clinical evaluation of a computer-controlled pressure support mode.

Authors:  M Dojat; A Harf; D Touchard; F Lemaire; L Brochard
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

9.  Respiratory, metabolic and hemodynamic effects of clonidine in ventilated patients presenting with withdrawal syndrome.

Authors:  Domniki Liatsi; Basilis Tsapas; Smaro Pampori; Matthew Tsagourias; Ioannis Pneumatikos; Dimitrios Matamis
Journal:  Intensive Care Med       Date:  2008-08-16       Impact factor: 17.440

10.  Respiratory effects of clonidine alone and combined with morphine, in humans.

Authors:  P L Bailey; R J Sperry; G K Johnson; S J Eldredge; K A East; T D East; N L Pace; T H Stanley
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

View more
  2 in total

1.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

2.  How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Authors:  Dan Longrois; Fabrice Petitjeans; Olivier Simonet; Marc de Kock; Marc Belliveau; Cyrille Pichot; Thomas Lieutaud; Marco Ghignone; Luc Quintin
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.